Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery

GENERAL SUMMARY

The incumbent provides enterprise-level strategic statistical leadership and oversight across all statistical aspects of assigned programs and the broader Biostatistics function; drives cross-functional collaboration, quantitative decision making, and development strategy for program(s); oversees the performance of Contract Research Organizations (CROs); develops and mentors statisticians and people leaders, and acts as Head of Biostatistics when needed.

MAJOR DUTIES & RESPONSIBILITIES:

Provides executive-level leadership and accountability for strategy (design, analysis/synthesis, interpretation and reporting, health authority response, publication strategy, and quantitative decision making) in the global development program
Leads senior-level collaborations with clinical, regulatory and other strategic functions to drive quantitative decision making and enable successful impact on robust drug development plans
Provides strategic oversight and guidance to staff members within 4DMT and in CROs in completing high quality study deliverables according to agreed timelines following quality standards.
Leads and/or sponsors the development and review of Policies, SOPs and other controlled documents for process improvement, inspection readiness, and operational efficiency.
Provides senior strategic statistical input in regulatory documents and scientific articles.
Leads data generation strategy for podium presentations and payor discussions.
Plays a critical role in shaping team development, succession planning, and contributing to departmental and functional strategy.
Stays abreast of, contributes to, and represents the organization on scientific advances in the field.
Other duties as assigned, nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time

QUALIFICATIONS:

Education:

PhD in Statistics, biostatistics or related fields or Masters with significant experience

Experience:

14+ years of pharmaceutical industry experience with a PhD, or 15+ years with an MS.

Hands-on experience working with CDISC standards and programming based on raw datasets, SDTM, and ADaM datasets.

10+ years of management experience, including leadership of senior technical talent and people managers

Other Qualifications/Skills:

Hands-on familiarity with common and advanced statistical methodology.
Strong knowledge of SAS programming concepts and techniques in the pharmaceutical; proficiency in tools such as SAS, EAST, and nQuery.
Knowledge/experience of global regulatory requirements in novel endpoints and rare diseases is a plus

Travel: <5%

Physical Requirements and Working Conditions:

Physical Activity - Repetitive motions: Making substantial movements (motions) of the wrists, hands, and/or fingers. Fingering: Picking, pinching, typing or otherwise working, primarily with fingers rather than with whole hand or arm as in handling. Talking: Expressing or exchanging ideas by means of the spoken word.
Physical Requirements - Sedentary work: Exerting up to 10 pounds of force occasionally and/or a negligible amount of force frequently or constantly to lift, carry, push, pull or otherwise move objects, including the human body. Sedentary work involves sitting most of the time. Jobs are sedentary if walking and standing are required only occasionally and all other sedentary criteria are met.
Working Conditions - The worker is not substantially exposed to adverse environmental conditions (as in typical office or administrative work).

Base salary compensation range: $330,000 - 390,000

Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.

4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.

Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities

About the company

4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.

Company Size

201-500

Company Stage

IPO

Headquarters

Emeryville, California

Founded

2013

Get referred to 4D Molecular Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

4FRONT-1 completed enrollment in February 2026; topline data arrives in Q2 2027.
4FRONT-2 finished enrollment in Q2 2026, extending 4D-150's pivotal catalyst stack.
Cash and Otsuka funding support operations into second half 2028, reducing near-term dilution pressure.

What critics are saying

4D-310's aHUS cases triggered FDA clinical hold in 2023; Fabry remains damaged.
Hercules debt matures June 2031; failed milestones trap 4DMT with expensive secured capital.
If 4D-150 Phase 3 misses in 2027, 4DMT loses its only near-term commercial path.

What makes 4D Molecular Therapeutics unique

4D-150 uses 4DMT's R100 vector for single-injection, multi-year anti-VEGF delivery.
Otsuka licensed 4D-150 APAC rights in October 2025, validating 4DMT's retina platform.
4D-710 achieved CFTR expression in cystic fibrosis lungs after aerosol delivery, a technical first.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Market Wire News

Oct 5th, 2026

4DMT to host Investor Day on October 21, 2026.

4DMT to host Investor Day on October 21, 2026. MWN-AI** Summary. 4D Molecular Therapeutics (Nasdaq: FDMT) is set to host an Investor Day on October 21, 2026, in New York City, focusing on its innovative product candidate 4D-150, aimed at revolutionizing the treatment of VEGF-driven retinal diseases. The event will commence at 10:30 AM ET and will feature presentations from 4DMT leadership, alongside a panel discussion with renowned retinal experts, including Dr. Arshad M. Khanani, Dr. Carl C. Awh, Dr. David Eichenbaum, and Dr. Sara J. Haug. These thought leaders are expected to provide valuable insights into the evolving clinical landscape and commercial strategy for 4D-150. 4D-150 is designed to serve as a foundational therapy for blinding retinal vascular diseases, providing sustained delivery of anti-VEGF biologics like aflibercept and anti-VEGF-C through a single intravitreal injection. This innovative approach aims to alleviate the treatment burden associated with frequent bolus injections that currently characterize the management of conditions such as wet age-related macular degeneration and diabetic macular edema, both of which are in Phase 3 clinical trials. In addition to 4D-150, 4D Molecular Therapeutics is advancing its second product candidate, 4D-710, the first known genetic medicine to effectively deliver and express the CFTR transgene in the lungs via aerosol delivery, targeting cystic fibrosis. The company is committed to developing disease-targeted therapeutics with the potential to significantly improve patients' lives. Investors interested in attending the event can register online, with a recorded version of the presentations made available for one year on the company's website. MWN-AI** Analysis. 4D Molecular Therapeutics (Nasdaq: FDMT) is gearing up for an Investor Day on October 21, 2026, where it aims to showcase the progress and future potential of its lead product candidate, 4D-150, designed to address VEGF-driven retinal diseases. With renowned retinal experts participating, this event is an excellent opportunity for investors to gain deeper insights into the company's clinical advancements and commercial strategy. 4D-150 stands out as a transformative biological therapy intended to deliver sustained anti-VEGF treatment through a single intravitreal injection. This innovation has the potential to significantly reduce the treatment burden for diseases such as wet age-related macular degeneration and diabetic macular edema, which are both in pivotal Phase 3 trials. The market for ocular therapeutics is robust, driven by the increasing prevalence of retinal diseases, and a successful outcome from these trials could position 4DMT as a market leader. Investors should pay attention to the expert panel discussions at the Investor Day, as insights from respected figures in ophthalmology could address the anticipated efficacy, safety, and market adoption of 4D-150. This event will allow stakeholders to evaluate the company's long-term vision and competitive positioning in a rapidly evolving biopharmaceutical marketplace. As of now, 4DMT represents a high-risk, high-reward investment given its therapeutic candidates are still undergoing clinical evaluation and have not received FDA approval. Investors should closely monitor the outcomes of the Phase 3 trials and responses during the Q&A to gauge potential market success. Overall, if clinical results are favorable, 4DMT could experience substantial growth, making it a compelling watch over the upcoming months. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. October 05, 2026 08:00:00 am * Company to share insights on the advancing clinical profile and commercial vision for 4D-150 * Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseases * Live event will take place in New York City on October 21, 2026 at 10:30am ET EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will host an Investor Day on Wednesday, October 21, 2026, in New York City. The live event will begin at 10:30am ET and include a Company presentation, KOL panel discussions and a live Q&A session. An archived copy of the webcast will be available for up to one year on the "Investors" section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events. About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), Backbone 4 Retina(TM) and the 4DMT logo are trademarks of 4DMT. All of its product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of its product candidates for the therapeutic uses for which they are being studied. Media: Jenn Gordon dna Communications [email protected] Investors: Julian Pei Head of Investor Relations and Strategic Finance [email protected] FAQ**. How does 4D Molecular Therapeutics Inc. (FDMT) plan to differentiate the multi-year sustained delivery system of 4D-150 from traditional treatment approaches in the management of VEGF-driven retinal diseases? 4D Molecular Therapeutics Inc. plans to differentiate 4D-150 by utilizing a multi-year sustained delivery system that targets the root causes of VEGF-driven retinal diseases, potentially reducing the frequency of treatments compared to traditional approaches. What insights do the renowned retinal experts believe will most significantly influence the commercial vision for 4D Molecular Therapeutics Inc. (FDMT) in the years following the launch of 4D-150? Renowned retinal experts believe advancements in targeted gene therapy and innovative delivery systems will significantly influence the commercial vision for 4D Molecular Therapeutics Inc. (FDMT) post-launch of 4D-150, enhancing treatment outcomes and market potential. Can you elaborate on any potential collaborations or partnerships 4D Molecular Therapeutics Inc. (FDMT) is pursuing to enhance the market launch strategy of 4D-150 in treating wet age-related macular degeneration and diabetic macular edema? As of now, specific details on collaborations or partnerships that 4D Molecular Therapeutics Inc. (FDMT) is pursuing for 4D-150's market launch strategy in treating wet age-related macular degeneration and diabetic macular edema have not been publicly disclosed. What key strategies will Molecular Therapeutics Inc. (FDMT) employ to educate physicians and patients about the benefits of reduced treatment burden associated with 4D-150 compared to current bolus injections? 4D Molecular Therapeutics Inc. will implement targeted educational campaigns, utilize digital platforms for information dissemination, conduct physician training sessions, and share patient testimonials to highlight the benefits of 4D-150 over traditional bolus injections. **MWN-AI FAQ is based on asking OpenAI questions about 4D Molecular Therapeutics Inc. (NASDAQ: FDMT).

MarketBeat

Aug 13th, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) announces quarterly earnings results.

4D Molecular Therapeutics (NASDAQ:FDMT) announces quarterly earnings results. August 13, 2026 Key points. * 4D Molecular Therapeutics missed earnings expectations: The company reported a quarterly loss of $1.04 per share versus the $1.02 consensus estimate, while revenue of $3.78 million exceeded expectations of $3.62 million. * Shares fell 1.9% to $11.65 after the results. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $29.75, although ratings range from "Strong Buy" to "Sell." * Insiders sold 197,226 shares worth approximately $2.2 million over the past 90 days, while institutional investors own 99.27% of the company's stock. * Five stocks we like better than 4D Molecular Therapeutics. 4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02), FiscalAI reports. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics stock down 1.9%. NASDAQ:FDMT traded down $0.22 during midday trading on Thursday, hitting $11.65. The stock had a trading volume of 705,798 shares, compared to its average volume of 787,133. 4D Molecular Therapeutics has a one year low of $5.97 and a one year high of $14.00. The company has a market capitalization of $609.06 million, a price-to-earnings ratio of -4.53 and a beta of 2.73. The stock has a 50-day moving average of $10.84 and a 200 day moving average of $9.83. Analyst ratings changes. FDMT has been the subject of a number of recent analyst reports. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Wall Street Zen downgraded 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Finally, B. Riley Financial initiated coverage on 4D Molecular Therapeutics in a report on Friday, July 31st. They set a "buy" rating and a $37.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.75. Insiders place their bets. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company's stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Kirn sold 12,415 shares of the company's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares of the company's stock, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 197,226 shares of company stock valued at $2,200,677. 7.90% of the stock is currently owned by corporate insiders. Institutional inflows and outflows. Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Martingale Asset Management L P lifted its holdings in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock worth $88,000 after buying an additional 1,303 shares during the period. Commonwealth Equity Services LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at $150,000. Brevan Howard Capital Management LP purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $143,000. ADAR1 Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth $145,000. Finally, Bridgeway Capital Management LLC lifted its stake in shares of 4D Molecular Therapeutics by 100.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company's stock worth $93,000 after purchasing an additional 12,516 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors. 4D Molecular Therapeutics company profile. 4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches. 4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider 4D Molecular Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list. While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Aktiencheck.de AG

Jun 29th, 2026

4DMT secures $200M credit facility from Hercules Capital

4D Molecular Therapeutics, a late-stage biotechnology company, has secured a strategic credit facility of up to $200 million from Hercules Capital. The California-based firm focuses on developing durable and disease-targeted therapeutics. The funding agreement was announced on 29 June 2026. No further details about the terms of the credit facility or its intended use were disclosed in the announcement.

Insider Monkey

May 20th, 2026

4D Molecular Therapeutics Inc (FDMT): gene therapy stock made for you?

4D Molecular Therapeutics Inc (FDMT): gene therapy stock made for you? Published on May 20, 2026 at 8:36 am by abdul rahman in news. 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is one of the best gene therapy stocks to buy in 2026. The stock has gained nearly 30% year-to-date and surged more than 190% over the past year. Looking ahead, analysts expect FDMT stock to almost triple in the next 12 months as the company continues to advance its clinical programs. On May 7, 4D Molecular Therapeutics reported its Q1 2026 results and issued operational updates. On the financial side, the company said that it expects to have enough cash to fund its operations at least into the second half of 2028. It closed Q1 with $458 million in cash, cash equivalents, and marketable securities. The company also expects to receive some payments under its arrangement with Otsuka. Regarding its clinical programs, 4D Molecular Therapeutics said it completed enrollment in the 4FRONT-1 Phase 3 trial of 4D-150 ahead of schedule. It said this demonstrates strong investigator and patient enthusiasm for the study. It expects topline data from this study in the first half of 2027. The company expects to complete enrollment in the 4FRONT-2 Phase 3 trial of 4D-150 in the back half of 2026 and expects topline data readout in the second half of 2027. 4D Molecular is developing 4D-150 as a therapy for blinding retinal vascular diseases. The lead indication is wet age-related macular degeneration, which is the subject of the 4FRONT Phase 3 studies. Another indication is diabetic macular edema. 4D Molecular is also advancing programs for geographic atrophy and cystic fibrosis therapies. California-based 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is a biotech company focused on genetic medicines. The company is developing advanced gene therapies that target rare and common diseases in areas like ophthalmology and pulmonology. While we acknowledge the risk and potential of FDMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than FDMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Yahoo Finance

May 11th, 2026

4D Molecular Therapeutics beats revenue expectations with $3M but analysts forecast 83% revenue decline for 2026

4D Molecular Therapeutics reported first-quarter revenues of $3.0 million, crushing expectations, though statutory losses reached $1.01 per share. Following the results, shares rose 7.4% to $10.14. Analysts covering the company have revised their 2026 forecasts, now expecting revenues of $15.0 million—an 83% reduction from the past 12 months. Per-share losses are projected to reach $3.92. Whilst analysts lifted revenue estimates, they also increased loss projections to reflect growth costs. The consensus price target remained at $28.22, with estimates ranging from $17.00 to $36.00 per share. Analysts forecast an annualised revenue decline of 91% by end-2026, contrasting sharply with the company's 32% annual growth over the past five years and the industry's projected 22% growth.

4D Molecular Therapeutics

Vice President of Biostatistics

About the job